EMBRACE | Jotup

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

Retrieved on:

火曜日, 4月 9, 2024

HER2, ILD, CPI, Survival, Progression-free survival, Central nervous system, Patient, CNS, History, Death, Eribulin, Spacecraft, MD, CBR, TPC, EMBRACE, Life, BCT, AACR, TSX, Therapy, Breast cancer, Safety, Poster, CMO, PFS, ADC, PD-1, Pharmaceutical industry

“ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.

Key Points:

“ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.
To our knowledge, there are no effective treatment options in this patient population for whom the progression-free survival prognosis is only a few weeks.
BriaCell will be monitoring ADC resistant patients in its ongoing pivotal Phase 3 study of Bria-IMT™ and CPI in advanced metastatic breast cancer.
Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study.

Embrace Pet Insurance's Impact: Over $1.1 Million Generated and Lifesaving Support for 2,500+ Pets in Two-Year-Span

Retrieved on:

火曜日, 3月 26, 2024

Partnership, EMBRACE, Pet, Cat, Dog, Mental health, Animal, Parent

Embrace Pet Insurance shines with 1600+ volunteer hours and strategic partnerships to empower communities and support pets.

Key Points:

Embrace Pet Insurance shines with 1600+ volunteer hours and strategic partnerships to empower communities and support pets.
Additional major highlights captured in Embrace Pet Insurance's 2023 Community Impact Report include:
"In 2023, we took our passion for pets to the next level," said Brian Macias, CEO of Embrace Pet Insurance.
Looking ahead, Embrace Pet Insurance is eager to expand its commitment to positively empowering nonprofits and animal welfare initiatives.
For more information about Embrace Pet Insurance and our services, please visit embracepetinsurance.com or call (800) EMBRACE.

Embrace Pet Insurance Reveals 2023's Top Pet Names, Breeds, and Claims

Retrieved on:

火曜日, 2月 6, 2024

Heart murmur, Policy, Embrace, EMBRACE, Cat, Family, Pet, Dog

In 2023, Embrace Pet Insurance experienced notable increases in individual claim amounts, with our highest covered claim surpassing the previous years by 16.5%--$48,534 for a small mixed breed dog with aspiration pneumonia and a heart murmur.

Key Points:

In 2023, Embrace Pet Insurance experienced notable increases in individual claim amounts, with our highest covered claim surpassing the previous years by 16.5%--$48,534 for a small mixed breed dog with aspiration pneumonia and a heart murmur.
Other notable covered claim amounts:
"2023 was a landmark year for Embrace, with our team expertly processing over 1 million claims and our family now growing to over 500,000 insured pets," said Brian Macias, CEO of Embrace Pet Insurance.
At Embrace, we're more than a pet insurance provider; we're at the forefront of pet health insights and industry innovation."
For more information about Embrace Pet Insurance and our services, please visit embracepetinsurance.com or call (800) EMBRACE.

Dxcover Announces Three New Clinical Trials for Brain, Colorectal and Lung Cancer Detection

Retrieved on:

火曜日, 1月 9, 2024

Dxcover Limited , a clinical-stage diagnostics company pioneering multi-omic spectral analysis (MOSA) for early detection of multiple cancers, today announced it is initiating three pivotal clinical trials measuring efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal and lung cancer.

Key Points:

Dxcover Limited , a clinical-stage diagnostics company pioneering multi-omic spectral analysis (MOSA) for early detection of multiple cancers, today announced it is initiating three pivotal clinical trials measuring efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal and lung cancer.
The company has launched its EMBRACE study, a 2,200-patient trial focused on the early detection of brain cancer.
Dxcover® Brain Cancer is a qualitative in vitro diagnostic (IVD) test analyzing blood serum by infrared spectroscopy to detect the signals indicative of brain cancer.
The Dxcover Brain Cancer test has been developed over four years with clinical support from NHS Lothian.

Over Half of Americans Consider Providing Foster Care but Majority Unsure if Eligible, Kidsave-Gallup Study Finds

Retrieved on:

木曜日, 11月 16, 2023

Knowledge, Perception, Research, Policy, Organization, Gallup, African Americans, EMBRACE, Mentorship, Hispanic and Latino Americans, Drug, Residential care, Black

WASHINGTON, Nov. 16, 2023 /PRNewswire/ -- In a new report, Americans' Views of U.S. Foster Care: Elevating Black Americans' Perspectives and Experiences, Kidsave and Gallup examine how the American public — especially Black Americans — view the foster care system and adoption from foster care. The findings show that almost two-thirds of the population know little (43%) or nothing (20%) about the U.S. foster care system, and just one in four (27%) have positive views about the system. The study aims to identify barriers to mentoring, fostering and adoption, with a focus on Black foster youth, to help increase the number of potential foster and adoptive parents.

Key Points:

Black Americans Show More Foster Care Knowledge, Adoption Engagement and Involvement in Programs with Children in Foster Care than Americans of Other Racial and Ethnic Backgrounds.
WASHINGTON, Nov. 16, 2023 /PRNewswire/ -- In a new report, Americans' Views of U.S. Foster Care: Elevating Black Americans' Perspectives and Experiences, Kidsave and Gallup examine how the American public — especially Black Americans — view the foster care system and adoption from foster care.
Two-thirds (68%) of Americans don't know if they are eligible to provide foster care, while 24% say they know they are eligible.
Black Americans report lower levels of confidence in key aspects of the U.S. foster care system.

Freewill Agency & Freewill Capital Hosts Successful Investment Immigration Summit in Vietnam, Empowering Global Citizenship and Wealth Management Dialogue

Retrieved on:

水曜日, 5月 31, 2023

Family, EMBRACE, Investment, Multimedia, Clothing, Real estate, Fintech

HO CHI MINH CITY, Vietnam, May 31, 2023 /PRNewswire/ -- Freewill Agency & Freewill Capital, successfully organized the Investment Immigration Summit in Vietnam on May, 2023.

Key Points:

HO CHI MINH CITY, Vietnam, May 31, 2023 /PRNewswire/ -- Freewill Agency & Freewill Capital, successfully organized the Investment Immigration Summit in Vietnam on May, 2023.
Freewill Agency & Freewill Capital are companies with experienced shareholders in the fields of Immigration, Investment, and Fintech.
The summit brought together industry leaders, experts, and high-net-worth individuals from around the world to discuss investment immigration, wealth management, and global citizenship.
EMBRACE BUSINESS OPPORTUNITIES AND POTENTIAL INVESTMENT PROJECTS FROM FREEWILL AGENCY & FREEWILL CAPITAL.

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

Retrieved on:

木曜日, 12月 1, 2022

2019–2022 Sudanese transition to democracy, Eribulin, FDA, Research, Safety, EMBRACE, Senior, Breast cancer, Eisai, Pharmaceutical industry

TOKYO, Dec 1, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10.

Key Points:

TOKYO, Dec 1, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10.
Eisai will present five eribulin-related abstracts, including a post hoc subgroup analysis from two pivotal Phase 3 studies (EMBRACE and Study 301), as well as:
- Real world use of eribulin following treatment with a P13K inhibitor, mostly in people with Hormone Receptor (HR)-positive/HER2-negative metastatic breast cancer.
- Preclinical data exploring a liposomal formulation of eribulin, in a Phase 1 expansion cohort for breast cancer, versus eribulin at the same dose, in patient-derived breast cancer xenografts.
There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on:

月曜日, 9月 12, 2022

These data were presented as a poster (Presentation: #259P) at the European Society for Medical Oncology (ESMO) Annual Meeting (#ESMO22), held virtually and in-person in Paris, France from September 9-13, 2022.

Key Points:

These data were presented as a poster (Presentation: #259P) at the European Society for Medical Oncology (ESMO) Annual Meeting (#ESMO22), held virtually and in-person in Paris, France from September 9-13, 2022.
HER2-low tumors express low amounts of the HER2 protein, but not enough to be considered HER2-positive.
HER2-low is defined as an IHC of 1+ or 2 with a negative ISH.
Of those patients, about 60% would now be considered to have the HER2-low subtype.

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022

Retrieved on:

火曜日, 9月 6, 2022

TOKYO, Sept 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13.

Key Points:

TOKYO, Sept 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13.
The study evaluated the combination of lenvatinib plus anti-PD-1 antibody pembrolizumab from Merck & Co., Inc., Rahway, NJ, USA versus lenvatinib monotherapy as a first-line treatment for patients with unresectable hepatocellular carcinoma.
To date, more than 15 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.
There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Michaels Predicts 2022 as the Year of “Mindful Making”

Retrieved on:

火曜日, 11月 16, 2021

View the full release here: https://www.businesswire.com/news/home/20211116005394/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20211116005394/en/
Michaels predicts 2022 as the year of "mindful making," plus eight trends to watch!
Michaels expects a focus on mindful making to continue through 2022, with some surprising trends putting a new spin on already popular makes.
At Michaels, we are inspired by our Makers and the incredible things they create, shares Andrea Manning, Senior Director of Trend, Design & Packaging at Michaels.
In 2022 we expect to see new and experienced Makers alike continue to practice mindful making, the idea of using arts and crafts to relax and find calm.